CompletedPhase 4

Intravitreal Aflibercept for Submacular Hemorrhage

South Korea29 participantsStarted 2015-12

Plain-language summary

The prognosis of exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage is generally poor. A recently developed anti-VEGF agent eyeliaTM is also a useful treatment option for exudative AMD. However, one major limitation of VIEW study was that lack of data regarding eyes with submacular hemorrhage. The purpose of the present study was to evaluate the efficacy of Eylea in submacular hemorrhage secondary to exudative AMD.

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. 50 years of older
. Newly diagnosed, treatment-naïve exudative AMD
. Fovea-involving submacular hemorrhage greater than 1 disc areas at diagnosis

Exclusion criteria

. History of previous treatment for neovascular AMD
. Greater than 15 disc diameter areas of hemorrhage extent
. History of vitreoretinal surgery
. History of glaucoma surgery, such as trabeculectomy or glaucoma implant surgery

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Changes in Early Treatment of Diabetic Retinopathy Study visual acuity Score

Timeframe: Changes from baseline in visual acuity at 56 weeks

Trial details

NCT IDNCT03169660

SponsorKim's Eye Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01-20

View on ClinicalTrials.gov More Exudative Age-related Macular Degeneration trials